In addition, considering the fact that cancer cells in general have overexpressed Cyclooxygenase-2 levels and higher fatty acid intake rates than normal cells and tissues [7–9, 50], we anticipate that our strategy will lead to fewer side effects and safer cancer treatment outcomes. This evidence concerns the gene PTGS2 and cancer.